Full Name
Bong Koh
Job Title
Managing Partner
Company
Venrock
Speaker Bio
Bong originally joined Venrock in 2009 and has been doing public and private investing since 2004. He did his medical training at Harvard’s Mass Eye & Ear Infirmary (ophthalmology), Stanford Hospital (internal medicine) and UCSF (pathology).
Bong works predominantly on Venrock’s public and cross-over biotech fund, Venrock Healthcare Capital Partners.
Bong has sat on the board of directors for Artiva Biotherapeutics, AveXis, Inc. (acquired by Novartis for .7 billion) and RayzeBio, Inc. (acquired by Bristol Myers Squibb for .1 billion). Bong sits on and has sat on the board of directors for two AAPI focused 501c3’s: ElevAAte and CACF.
Bong earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School.
Bong works predominantly on Venrock’s public and cross-over biotech fund, Venrock Healthcare Capital Partners.
Bong has sat on the board of directors for Artiva Biotherapeutics, AveXis, Inc. (acquired by Novartis for .7 billion) and RayzeBio, Inc. (acquired by Bristol Myers Squibb for .1 billion). Bong sits on and has sat on the board of directors for two AAPI focused 501c3’s: ElevAAte and CACF.
Bong earned his B.A. from Yale University, his M.D. from the University of California, San Francisco, and an M.B.A. from Harvard Business School.
Speaking At
